U.S. Dendritic Cell Cancer Vaccine Market Size & Outlook
U.S. dendritic cell cancer vaccine market, 2018-2030 (US$M)
Related Markets
U.S. dendritic cell cancer vaccine market highlights
- The U.S. dendritic cell cancer vaccine market generated a revenue of USD 379.0 million in 2023 and is expected to reach USD 851.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 12.3% from 2024 to 2030.
- In terms of segment, sipuleucel-t (provenge) was the largest revenue generating vector type in 2023.
- Other Vector Type is the most lucrative vector type segment registering the fastest growth during the forecast period.
Dendritic cell cancer vaccine market data book summary
| Market revenue in 2023 | USD 379.0 million |
| Market revenue in 2030 | USD 851.4 million |
| Growth rate | 12.3% (CAGR from 2023 to 2030) |
| Largest segment | Sipuleucel-t (provenge) |
| Fastest growing segment | Other Vector Type |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sipuleucel-T (Provenge), CreaVax, Other Vector Type |
| Key market players worldwide | GlaxoSmithKline, 3M Co, Perseus Mining Ltd, Renovaro Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 58.1% of the global dendritic cell cancer vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. dendritic cell cancer vaccine market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 44.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Dendritic Cell Cancer Vaccine Market Scope
Dendritic Cell Cancer Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. dendritic cell cancer vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dendritic cell cancer vaccine market will help companies and investors design strategic landscapes.
Sipuleucel-t (provenge) was the largest segment with a revenue share of 84.22% in 2023. Horizon Databook has segmented the U.S. dendritic cell cancer vaccine market based on sipuleucel-t (provenge), creavax, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Dendritic Cell Cancer Vaccine Vector Type Outlook (Revenue, USD Million, 2018-2030)
- Sipuleucel-T (Provenge)
- CreaVax
- Other Vector Type
- U.S. Dendritic Cell Cancer Vaccine Indication Outlook (Revenue, USD Million, 2018-2030)
- Pediatrics
- Adults
Reasons to subscribe to U.S. dendritic cell cancer vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. dendritic cell cancer vaccine market databook
-
Our clientele includes a mix of dendritic cell cancer vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dendritic cell cancer vaccine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. dendritic cell cancer vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. dendritic cell cancer vaccine market outlook size, by vector type, 2018-2030 (US$M)
U.S. Dendritic Cell Cancer Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
